{
  "indication": "cancer",
  "drug_name": "IL-2",
  "drug_form": "low-dose IL-2",
  "drug_generic_name": "Aldesleukin",
  "research_plan": {
    "disease": "cancer",
    "research_areas": [
      "market_opportunity_analysis"
    ],
    "sections": [
      {
        "name": "market_opportunity_analysis",
        "description": "Assess the market and opportunity for low-dose IL-2 in cancer.",
        "required_evidence_types": [
          "pubmed",
          "clinicaltrials"
        ],
        "key_questions": [
          "What is the potential market size for cancer treatments in the US?",
          "What is the annual incidence of new cancer diagnoses in the US?",
          "What specific unmet needs in cancer treatment can low-dose IL-2 address?",
          "How does low-dose IL-2 differentiate from current and pipeline competitors?"
        ],
        "scope": "Focus on market opportunity for low-dose IL-2 in cancer."
      }
    ]
  }
}
